Universal Health Services (UHS) Q4 2025 earnings review
Solid Top-Line Growth Masked by Cash Flow Divergence
UHS delivered a 9.1% revenue increase and an 11% bump in Adjusted Net Income in Q4, closing out a strong 2025. However, the quality of earnings raises a red flag: while FY25 Net Income surged 30%, Operating Cash Flow fell 10%. This divergence is driven by a massive spike in Accounts Receivable tied to delayed Medicaid supplemental payments and new hospital ramp-ups. Looking ahead, FY26 guidance projects decelerating top-line and EBITDA growth, signaling that pricing power might not be enough to sustain the current momentum if volume continues to stagnate.
🐂 Bull Case
Across both Acute and Behavioral segments, revenue per adjusted admission/day grew over 5% YoY in Q4. The company continues to successfully offset flat volume with robust rate increases.
UHS repurchased $899.3M in stock during FY25. With a freshly authorized $1.5B expansion to the repurchase program, management has a massive lever to support EPS even as operational growth decelerates.
🐻 Bear Case
Operating cash flow dropped $203M YoY despite a $348M increase in net income. The $385M unfavorable change in accounts receivable highlights growing liquidity friction from government payers.
Recent legislation attaching work and community service requirements to Medicaid eligibility will likely limit enrollment and reduce revenues, creating a structural headwind for the coming years.
⚖️ Verdict: ⚪
Neutral. Management is executing flawlessly on pricing and shareholder returns, but the growing reliance on delayed Medicaid supplemental payments and decelerating FY26 growth targets warrant caution.
Key Themes
Cash Flow Diverges from Profitability Narrative
A major contradiction emerged in the FY25 results: Reported Net Income soared, but Net Cash Provided by Operating Activities fell from $2.067B in FY24 to $1.864B in FY25. This reversing trend is directly tied to a $385M unfavorable change in accounts receivable. Specifically, $145M is locked up in various Medicaid supplemental payment programs, and another $50M is tied to two new hospitals in Las Vegas and Washington, D.C. Earnings quality is deteriorating as paper profits outpace actual cash collection.
Macro: Medicaid Work Requirements Threaten Enrollment
Management explicitly flagged July 2025 legislation that attaches work and community service requirements to Medicaid eligibility. This macro shift is expected to limit Medicaid enrollment and eliminate certain exchange premium tax credits beyond 2025. As these provisions take effect, UHS expects a structural reduction in revenues and a corresponding spike in uncompensated care at its facilities.
Volume Stagnation in Acute Care
Same-facility adjusted admissions in the Acute Care segment were perfectly flat (0.0%) in Q4, while adjusted patient days contracted by 0.7%. All revenue growth in this segment is currently being driven by pricing. Relying entirely on rate hikes without underlying utilization growth is a decelerating and ultimately unsustainable strategy.
Behavioral Health Pricing Outperformance
The Behavioral Health segment showed stable, robust performance. Q4 Same-facility revenue per adjusted admission increased 5.3%, and revenue per adjusted patient day increased 5.6%. Unlike Acute Care, this segment also maintained positive volume metrics (admissions up 1.8%). This dual-engine growth solidifies Behavioral Health as the company's most reliable operational driver.
Generative AI Investment Yields Massive Gain
Highlighting a successful technology venture, UHS recorded a massive $93.3M pre-tax ($71.5M after-tax) unrealized gain in Q4 connected to its minority ownership in a healthcare generative artificial intelligence company. While non-operational, this indicates management is successfully leveraging capital into high-growth health-tech innovations, providing a significant boost to the balance sheet.
Relentless Share Repurchase Execution
UHS repurchased 1.46 million shares in Q4 for $333.5M, bringing the FY25 total to 4.65 million shares for $899.3M (average price $193/share). Supported by a fresh $1.5B authorization from October 2025, the company still has $1.425B available. This aggressive capital return acts as a floor for the stock and mathematically forces EPS higher even in a low-growth environment.
Other KPIs
Up 10.4% YoY from $614.6 million in 24Q4. The Adjusted EBITDA margin remained stable at 15.1%, indicating that the company is effectively passing through labor and supply inflation via higher pricing to commercial and government payers.
Accelerating significantly. AR jumped nearly 20% YoY from $2.17B at the end of 2024. This massive buildup is a drag on working capital and ties back directly to the delays in state supplemental Medicaid disbursements.
Guidance
Decelerating. The midpoint of $18.603B implies 7.1% YoY growth, a step down from the 9.7% growth achieved in FY25. This suggests management expects the pricing leverage seen in 2025 to moderate or volume headwinds to persist.
Decelerating. The midpoint implies 4.8% YoY growth, significantly lower than the 14.9% growth achieved in FY25. This indicates expected margin compression, likely due to the structural rollout of Medicaid work requirements and stabilizing commercial pricing.
Decelerating. The midpoint implies 8.5% YoY growth, down from the massive 30% jump in FY25. Given the aggressive share buyback program, an 8.5% EPS growth target implies very muted underlying net income expansion.
Stable. The midpoint of $1.025B is roughly in line with the $1.015B spent in FY25, indicating that management is maintaining its steady cadence of facility expansion and maintenance without aggressively ramping up CapEx.
Key Questions
Medicaid AR Collections Timeline
Accounts Receivable ballooned by $385M this year, with $145M tied directly to Medicaid supplemental programs. What is your realistic timeline for converting these specific receivables into cash, and is there any risk of write-downs if state budgets tighten?
Acute Care Volume Strategy
Same-facility adjusted admissions were flat in Q4 and patient days were negative. If pricing power begins to normalize, what specific operational levers will you pull to reignite volume growth in the Acute Care segment?
Generative AI Monetization
You recorded a massive $93M pre-tax gain from your minority stake in a healthcare generative AI company. How is UHS integrating this technology into its own clinical or revenue cycle operations to drive tangible margin improvements?